Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older of any race or gender
- People who are generally healthy, or people who have been diagnosed with Alzheimer's disease
Who may not be able to join:
- People who have had an allergic reaction to the imaging agent 18F-Fluselenamyl or any of its ingredients
- People who have had an allergic reaction to the imaging agent 11C-PIB or any of its ingredients
- People who are unable to give written consent themselves and do not have a legally authorised representative who can give consent on their behalf
- People who are unwilling or unable to have the injections required for PET scan imaging
- People who are unwilling or unable to undergo an MRI scan (confirm with trial site which parts of the trial this applies to)
- People with any health condition that, in the investigator's opinion, could increase risk, make it hard to tolerate the study procedures, or interfere with data collection — for example, serious kidney or liver problems or advanced cancer
- People who are currently pregnant or breastfeeding
- People who have taken part in other research studies involving radioactive agents within the past 12 months, where the combined radiation exposure would exceed the limits set by US federal regulations
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Tammie Benzinger, MD., PhD, Washington University School of Medicine
Phone: 314 273 6140
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To evaluate the safety of the new formulation of Fluselenamy PET Imaging in 8 healthy adult normal volunteers.; PET imaging of [18F]-Fluselenamyl in healthy normal control participants and participants with mild cognitive impairment.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.